
sourcing the best research evidence in ophthalmology
Hydrus Microstent for Lowering IOP in Glaucoma Patients Undergoing Cataract Surgery (HORIZON)
June 1, 2021
Clinical trial
Three-Year Findings of the HORIZON Trial: A Schlemm Canal Microstent for Pressure Reduction in Primary Open-Angle Glaucoma and Cataract.
Ahmed IIK, Rhee DJ, Jones J, Singh IP, Radcliffe N, Gazzard G, Samuelson TW, Ong J, Singh K; HORIZON Investigators.
Main finding: Combined CS and microstent placement for mild to moderate POAG is safe, more effective in lowering IOP with fewer medications, and less likely to result in further incisional glaucoma filtration surgery than CS alone at 3 years
- Purpose: To compare cataract surgery with implantation of Hydrus microstent vs cataract surgery alone in patients with Primary Open Angle Glaucoma.
- Study type: Randomized controlled trial
- Condition: Primary Open angle glaucoma
Participants: Visually significant age-related cataract and Primary open angle glaucoma
-modified diurnal IOP 22-34mmHg at baseline
- n=369 eyes
Intervention:
Group 1: Phacoemulsification + Hydrus Microstent implantation
Group 2: Phacoemulsification alone
Phaco + Hydrus | Phaco alone | |
---|---|---|
Mean number of medications | 0.4 | 0.8 |
Medication-free | 73% | 48% |
Proportion with IOP 18mmHg or less without medications | 56.2% | 34.6% |
Probability of incisional glaucoma surgery | 0.6% | 3.9% |
January 1, 2019
Clinical trial
A Schlemm Canal Microstent for Intraocular Pressure Reduction in Primary Open-Angle Glaucoma and Cataract: The HORIZON Study.
Samuelson TW, Chang DF, Marquis R, Flowers B, Lim KS, Ahmed IIK, Jampel HD, Aung T, Crandall AS, Singh K.
Main finding: There was a superior reduction in intraocular pressure and medication use in patients with mild-moderate POAG undergoing cataract surgery and Hydrus microstent implantation vs cataract surgery alone.
- Purpose: To compare cataract surgery with implantation of Hydrus microstent vs cataract surgery alone in patients with Primary Open Angle Glaucoma.
- Study type: Randomized controlled trial
- Condition: Primary Open angle glaucoma
Participants: Visually significant age-related cataract and Primary open angle glaucoma
-modified diurnal IOP 22-34mmHg at baseline
- n=369 eyes
Intervention:
Group 1: Phacoemulsification + Hydrus Microstent implantation
Group 2: Phacoemulsification alone
Time period | Phaco + Hydrus | Phaco alone | |
---|---|---|---|
Proportion with unmedicated modified diurnal IOP was reduced by ≥20% | 24-months | 77.3% | 57.8% |
Mean reduction in unmedicated modified diurnal IOP | 24-months | -7.6mmHg | -5.3mmHg |
Mean number of medications | Baseline | 1.7 | 1.7 |
24-months | 0.3 | 0.7 |
Source Archive